Horwitz et al. [35] evaluated cerdulatinib (a JAK1, 2, and 3 inhibitor), 30 mg, twice-daily efficacy in a phase II trial with 98 patients with refractory/relapsed CTCL or peripheral T cell lymphoma (PTCL), who at least received one prior systemic therapy. This evidence concerns the gene JAK1 and primary cutaneous T-cell non-Hodgkin lymphoma.